For the first time in the program's history, Medicare is now covering prescription weight-loss drugs for eligible seniors, not just when those medications are prescribed for diabetes or heart disease, but specifically for obesity.
The Medicare GLP-1 Bridge, a pilot program announced and launched by the Centers for Medicare & Medicaid Services on July 1, 2026, gives qualifying Part D enrollees access to Wegovy, Zepbound KwikPen, or Foundayo for a fixed $50 monthly copay. The program runs through December 31, 2027, and is the clearest coverage expansion for GLP-1 obesity medications in Medicare's history.
An estimated 3.8 million Medicare beneficiaries meet the clinical eligibility criteria, according to a KFF analysis — roughly 8 percent of the 47.5 million Part D plan members nationally.
Why This Matters
GLP-1 medications such as Wegovy (semaglutide) and Zepbound (tirzepatide) have reshaped obesity treatment over the past several years, producing average weight loss of 15 to 22 percent of body weight in clinical trials. Until yesterday, seniors on Medicare could access these drugs only if they were prescribed to treat Type 2 diabetes, obstructive sleep apnea, or — for certain formulations of Wegovy — cardiovascular disease risk.
That left millions of older adults with obesity unable to access the medications through their federal insurance, even as commercially insured patients and Medicaid enrollees in some states gained coverage.
Cash prices for GLP-1 drugs remain high. The Zepbound KwikPen can cost up to $699 per month at full price. Wegovy injections range from $149 to $699 monthly, depending on dose. The Bridge program's $50 flat copay — which does not increase as dosage increases — represents a dramatic reduction in cost for eligible enrollees.
What We Know So Far
The Medicare GLP-1 Bridge officially began July 1, 2026. Here are the key program parameters:
- Covered drugs : Wegovy (injection and daily pill), Zepbound KwikPen (weekly injection), and Foundayo (daily pill)
- Copay : $50 for a 30-day supply, regardless of dose or drug formulation
- Program duration : July 1, 2026 through December 31, 2027
- Enrollment requirement : Active enrollment in a Medicare Part D standalone prescription drug plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD)
- Prior authorization : Required; the prescriber must submit a prior authorization form to a centralized CMS processor — not to the patient's individual plan
- Copay counting : The $50 copay does not count toward the Part D annual deductible or the $2,100 out-of-pocket cap for 2026
The program operates outside the standard Part D payment flow, meaning individual plans do not carry financial risk for Bridge program drugs.
Do You Qualify? The Clinical Criteria
The Medicare.gov eligibility page outlines three clinical pathways to qualify:
Pathway 1 — BMI of 35 or higher: Patients with a body mass index of 35 or above are eligible regardless of other health conditions.
Pathway 2 — BMI of 30 to 34.99 with qualifying conditions: Patients at this BMI level qualify if they have at least one of the following: diastolic heart failure (heart failure with preserved ejection fraction), uncontrolled high blood pressure, or chronic kidney disease.
Pathway 3 — BMI of 27 or higher with additional conditions: Patients at this lower BMI threshold qualify if they have prediabetes or peripheral artery disease.
Important exception: Patients who are already receiving a GLP-1 drug through Medicare Part D for conditions such as Type 2 diabetes or sleep apnea are not eligible to also use the Bridge program for those same medications. Patients currently on a GLP-1 through a different payor — such as employer insurance or a private plan — may become eligible if they enroll in Part D.
Providers must also certify that the GLP-1 drug is being prescribed as part of a lifestyle program that includes diet and exercise guidance.
Where Seniors Face the Most Barriers
The prior authorization process for the Bridge program is handled through a centralized CMS processor — a new administrative layer that is unfamiliar to most physicians and pharmacies. This means that even seniors who meet all clinical criteria may experience delays in accessing the medication while providers and pharmacies navigate the new system.
Patients receiving the Extra Help low-income subsidy (also known as Medicare's Low Income Subsidy) cannot apply that assistance to Bridge program copays. The $50 copay is fixed and cannot be reduced through existing low-income support mechanisms — a limitation that creates an access barrier for some of the most financially vulnerable Medicare enrollees.
What Doctors and Experts Say
Juliette Cubanski, vice president and director of Medicare policy at KFF, described the access milestone alongside its practical caveats. She noted that patients who gain access through the Bridge program could face an uncertain coverage situation when the program ends December 31, 2027.
"In the short term, we have this temporary program, and then no clear path forward yet as to what will happen at the end of 2027," Cubanski told CBS News.
Dr. Kevin Schulman, a professor of medicine at Stanford University, noted that the Bridge program will produce real-world data on GLP-1 utilization among Medicare beneficiaries — data that CMS will use to determine whether to move forward with a longer-term coverage model. "In the end, this program will provide an interesting real-life experiment assessing the benefit of improving access to GLP-1s on overall healthcare spending," Schulman told Healthline.
Dr. Kelley, referenced in Healthline's coverage, emphasized that medication access is only part of the picture. "While the medications can really jump-start weight loss, changing habits is essential to maintaining those losses and remaining at a healthy weight," Kelley said.
What the Evidence Shows — and What It Does Not
The clinical evidence base for GLP-1 drugs in obesity management is robust. In large randomized controlled trials, semaglutide (the active ingredient in Wegovy) produced average weight loss of approximately 15 percent of body weight over 68 weeks. Tirzepatide (the active ingredient in Zepbound) demonstrated average weight reduction of 20 to 22 percent in the SURMOUNT trials.
However, the Bridge program is structured as a temporary demonstration, not a permanent benefit. Multiple studies have shown that the majority of patients who discontinue GLP-1 therapy regain most of the weight they lost within 12 months. If the Bridge program ends on its current schedule in December 2027 without a successor policy in place, patients could lose access to medications they have been taking for over a year — a concern that both CMS and patient advocates have flagged publicly.
MedicalDaily Evidence Check
- Program type : CMS temporary demonstration (pilot)
- Eligible enrollees (estimated) : 3.8 million Medicare Part D beneficiaries (KFF, 2026)
- Drug options : Wegovy (injection/pill), Zepbound KwikPen, Foundayo (pill)
- What it covers : GLP-1 drugs prescribed solely for obesity
- Key limitation : Program ends December 31, 2027; $50 copay does not count toward Part D out-of-pocket limits; prior authorization required; Extra Help cannot reduce the copay
- What readers should know : Eligibility requires active Part D enrollment plus clinical BMI/condition criteria; consult a physician to initiate the prior authorization process
Who Faces the Greatest Risk Without This Coverage?
Seniors who are most likely to benefit from the Bridge program — and who face the greatest health risk without coverage — include:
- Adults 65 and older with obesity-related cardiovascular conditions, Type 2 diabetes risk factors, or joint disease limiting physical activity
- Seniors on fixed incomes who previously could not afford GLP-1 drugs at cash prices
- Medicare beneficiaries in rural areas with limited access to bariatric surgery or obesity medicine specialists
- Older adults with a family history of diabetes, heart disease, or metabolic syndrome
What You Can Do Now
- Check your eligibility. The Medicare GLP-1 Bridge eligibility tool at Medicare.gov allows you to answer a few questions to determine if you likely qualify.
- Talk with your primary care provider. Your doctor must submit a prior authorization to the CMS central processor before you can fill the prescription. Bring your most recent BMI measurement and a list of relevant diagnoses to the appointment.
- Confirm your Part D enrollment. Only enrollees in a standalone Medicare Part D plan or a Medicare Advantage plan with drug coverage (MA-PD) qualify. If you are on original Medicare without Part D, you are not currently eligible for the Bridge program.
- Contact 1-800-MEDICARE. If you have questions about eligibility or want to check on a pending prior authorization, CMS's helpline is available around the clock.
- Understand what happens at the end of 2027. Ask your provider now to document your clinical criteria in your medical record. If coverage eventually shifts to a different program, having that documentation will support future prior authorization requests.
Cost and Access: What Patients Should Know
The $50 Bridge program copay is the same for all covered drugs and all dosage levels. However, because the copay does not apply toward the Part D deductible or out-of-pocket cap, patients paying $50 monthly for a GLP-1 drug through the Bridge program will still need to reach Part D spending thresholds through their other medications.
Patients who cannot access the Bridge program but want to compare prices for covered GLP-1 drugs may use CMS's TrumpRx.gov drug price comparison tool or GoodRx's free coupon program, which offers introductory prices of $149 to $199 for the first two fills of certain GLP-1 doses at participating pharmacies.
What Happens Next
CMS will collect GLP-1 utilization and clinical outcome data from the Bridge program throughout its 18-month run and share those findings with Part D plan sponsors. That data will inform whether and how to implement the BALANCE model — the proposed longer-term GLP-1 coverage program that CMS delayed in April 2026 for Part D, though it did launch in Medicaid in May 2026.
Updated program guidance and any changes to the prior authorization process will be posted at CMS.gov. MedicalDaily will report on any changes to coverage rules, eligibility criteria, or program extensions.
The Bottom Line
The Medicare GLP-1 Bridge is a meaningful, time-sensitive coverage opportunity for eligible seniors — and today, July 2, 2026, is the first full day they can use it. The eligibility criteria are specific, and the prior authorization process requires coordination with a physician, but for the estimated 3.8 million beneficiaries who qualify, the program reduces a medication that previously cost hundreds of dollars monthly to a fixed $50 copay. If you or a family member on Medicare has obesity and meets the clinical criteria, the first step is a conversation with a doctor — now, while the program is fully operational.
